USPTO awards Medicis restored transparent an eye to SOLODYN Extended Save Tablets
Medicis (NYSE:MRX) today announced that the Mutual States Prominent and Trademark Role (USPTO) has issued U.S. Copyright No. 7,790,705 common to the spurn of SOLODYN® (minocycline HCI, USP) Extended Publicity release Tablets. The modern control, entitled "Minocycline Enunciated Dosage Forms allowing for regarding the Treatment of Acne," relates to the consume of dosage forms of SOLODYN which prepare for around 1 mg/kg dosing based on the congress dialect heft of the human being, and expires in 2027.
"We are pleased as punch to confirm this unusual prominent during SOLODYN, the most fixed branded dermatology artefact in the Combined States and foremost dermatology issue generally dollars worldwide," said Jonah Shacknai, Chairman and Chief President Bureaucrat of Medicis. "We rely upon SOLODYN has untested attributes which determine it from other forms of minocycline. This different licence represents another critical milestone in maintaining the SOLODYN franchise. We into these issued self-evident claims commitment enrich the growing intellect quirk demesne of our SOLODYN brand."
SOLODYN has three other issued patents. U.S. Conspicuous No. 5,908,838, which expires in 2018, relates to the take of the SOLODYN unparalleled dismissal rate. U.S. Unmistakable No. 7,541,347, which expires in 2027, relates to the squander of the 90 mg dosage construction of SOLODYN. U.S. Physical No. 7,544,373, which expires in 2027, relates to the layout of the 90 mg dosage originate of SOLODYN. On April 2, 2010, the USPTO issued a Announce of Rebate respecting the Company’s U.S. Claim No. 11/166,817. The Theatre troupe also has a calculate of additional U.S. certificate of invention applications associated with the SOLODYN program on categorize at the USPTO.
Source Medicis
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
